Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Groundbreaking Diabetes Drug Headlines Approval Bonanza

The European Union's CHMP -- the regulatory body that helps the European Medicines Agency decide whether or not a drug should be approved -- issued a slew of decisions this week, including a positive opinion for Johnson & Johnson's (NYSE: JNJ  ) type 2 diabetes drug Inokana on Friday. This therapeutic, which belongs to the growing SGLT2 inhibitor drug class and already received approval in the U.S., will face competition from Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca's (NYSE: AZN  ) drug Forxiga if it gets on the EU market. In the following video, analysts David Williamson and Max Macaluso discuss the CHMP's decision, and competitors in this space, including Merck's (NYSE: MRK  ) top-selling medication Januvia.

Nine Rock Solid Dividends
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The relevant video segment can be found between 0:00-2:33.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2648003, ~/Articles/ArticleHandler.aspx, 9/28/2016 1:44:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,223.88 -4.42 -0.02%
S&P 500 2,159.30 -0.63 -0.03%
NASD 5,298.49 -7.22 -0.14%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 1:28 PM
JNJ $119.00 Down -0.22 -0.18%
Johnson and Johnso… CAPS Rating: *****
AZN $33.81 Up +0.20 +0.60%
AstraZeneca CAPS Rating: ****
BMY $55.04 Down -0.70 -1.26%
Bristol-Myers Squi… CAPS Rating: ****
MRK $62.89 Up +0.32 +0.51%
Merck and Co. CAPS Rating: ****